Long-lasting delivery of HIV prevention medications
Systemic Sustained Release Delivery of Antiretroviral Agents for HIV Prevention
This study is testing a new way to deliver HIV prevention medications that could make it easier for people to stay protected, with options for taking them less often, like once a month or even less frequently.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oak Crest Institute of Science NIH-funded |
| Lab location | 1 site (Monrovia, United States) |
| Project ID | NIH-10854871 on NIH RePORTER |
What this research studies
This research focuses on developing a new method for delivering antiretroviral medications to prevent HIV infection. By creating long-acting formulations that require less frequent dosing, the study aims to improve adherence to HIV prevention strategies. Patients will benefit from a more convenient and effective way to protect themselves from HIV, as the new delivery system could potentially allow for monthly or even less frequent dosing. The research involves clinical evaluations of these new formulations to ensure their safety and effectiveness.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of contracting HIV who may benefit from long-acting preventive treatments.
Not a fit: Patients who are already HIV positive or those who do not have risk factors for HIV infection may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and convenient method for HIV prevention, significantly reducing new infection rates.
How similar studies have performed: Previous research has shown success with long-acting formulations in other areas of medicine, indicating potential for similar advancements in HIV prevention.
Where this research is happening
Monrovia, United States
- Oak Crest Institute of Science — Monrovia, United States (Active)
Researchers
- Principal investigator: Baum, Marc Michael — Oak Crest Institute of Science
- Study coordinator: Baum, Marc Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.